TherapeuticsMD full-year 2023 net loss $7.7M, cash $4.3M; strategic review ongoing

TherapeuticsMD, Inc.

Net loss from continuing operations $(7.7)M ($(0.74) per share) vs $1.1M income ($0.12) in 2022.
Gross license royalties $4.5M under Mayne License; net recognized $1.3M revenue and $0.5M other income.
Operating expenses fell 85.4% to $9.8M, reflecting transition from commercial pharma to royalty model.
Cash and equivalents $4.3M at Dec 31, 2023; company continues exploring strategic alternatives.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TherapeuticsMD, Inc. reported the full year ended December 31, 2023 results: net income Net loss from continuing operations was $(7.7) million, or $(0.74) per basic and diluted common share, EPS $(0.74) per basic and diluted common share.

Period: the full year ended December 31, 2023
Net income: Net loss from continuing operations was $(7.7) million, or $(0.74) per basic and diluted common share
EPS: $(0.74) per basic and diluted common share
Result: reported results

Exact text from the filing

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-027998

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.